Moderna Revenue and Competitors

Boston, MA USA

Location

$2.7B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Moderna's estimated annual revenue is currently $11.8B per year.(i)
  • Moderna's estimated revenue per employee is $1,473,225
  • Moderna's total funding is $2.7B.
  • Moderna's current valuation is $83B. (January 2022)

Employee Data

  • Moderna has 8030 Employees.(i)
  • Moderna grew their employee count by 26% last year.

Moderna's People

NameTitleEmail/Phone
1
Principal Product Owner, SAP Order to CashReveal Email/Phone
2
Director, Business Process Owner (AP/T&E)Reveal Email/Phone
3
Executive Director, Business Development & Corporate StrategyReveal Email/Phone
4
Sr Specialist ERP and CMO ReconciliationReveal Email/Phone
5
Chief Staff, Research and Early DevelopmentReveal Email/Phone
6
CMO OperationsReveal Email/Phone
7
CSO, External Research Ventures (XRV)Reveal Email/Phone
8
Chief Architect, VPReveal Email/Phone
9
Chief Staff, Director Corporate Security OperationsReveal Email/Phone
10
CMO Operations Lead Moderna ItalyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Moderna?

Moderna is a leader in the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, an entirely new class of medicines that directs the body?s cells to produce intracellular or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals. With its breakthrough platform, Moderna is creating mRNA medicines for a wide range of diseases and conditions, in many cases by addressing currently undruggable targets or underserved areas of medical need. Moderna is developing its innovative mRNA medicines for infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases, through solely controlled programs and collaborations with strategic partners. Headquartered in Cambridge, Mass., privately held Moderna currently has strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc (MRK) and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation. In 2017 Moderna was ranked a top biopharma industry employer by Science Magazine and a Top Place to Work by the Boston Globe. To learn more, visit www.modernatx.com.

keywords:N/A

$2.7B

Total Funding

8030

Number of Employees

$11.8B

Revenue (est)

26%

Employee Growth %

$83B

Valuation

N/A

Accelerator

Moderna News

2022-04-19 - University of Virginia study gives nod to Moderna vaccine for the most at risk of COVID

The University of Virginia recently tracked its COVID-vaccinated employees who wanted to participate in a study, then monitored the...

2022-04-17 - Is Trending Stock Moderna, Inc. (MRNA) a Buy Now?

Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

2022-04-17 - Polish health minister upbeat on Moderna vaccine talks

Poland can reach a compromise with Moderna on increasing the flexibility of COVID-19 vaccine contracts, the health minister said on Friday,...

2021-10-26 - Moderna Announces Swissmedic Authorizes Booster Dose of Moderna's COVID-19 Vaccine

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Swissmedic has authorized a booster dose of Spikevax, the Company’s vaccine against COVID-19, at the 50 µg dose level in particularly vulnerable individuals 12 years of ...

2021-10-25 - Moderna : Announces European Medicines Agency's Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna's COVID-19 Vaccine in the European Union

Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that a booster dose of Spikevax, the Company’s vaccine ag ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1967.3M96916%N/A
#2
$3400M97846%$35M
#3
$11100M10056-10%N/A
#4
$3904M10328N/AN/A
#5
$1180M104076%$100.5M